Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals, Inc. reports developments as a Nasdaq-listed biopharmaceutical company focused on the discovery, development and commercialization of medicines for human disease. Company news commonly covers pipeline updates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders and other cardiometabolic indications, including clinical data presentations for sotagliflozin and pilavapadin.
Recurring updates also include operating and financial results, regulatory interactions, material agreements, financing arrangements and governance or shareholder-voting matters. Coverage of LXRX often connects capital-structure actions with the resources used to advance clinical and preclinical drug candidates.
Lexicon Pharmaceuticals (Nasdaq:LXRX) announced that company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:00 p.m. ET in New York City.
The live event and replay will be available via the Events page of Lexicon's investor website.
Lexicon Pharmaceuticals (Nasdaq:LXRX) announced that management will take part in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq World Headquarters in New York City on May 19, 2026. A live webcast and replay will be available on the company’s investor relations Events page.
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q1 2026 results and pipeline updates on May 7, 2026. Key points: Total revenue $21.1M (including a $20.0M Novo Nordisk milestone), cash, investments and restricted cash $199.7M, and a $100M Hercules loan facility with $55M funded.
Clinical highlights: SONATA-HCM enrollment expected mid-2026, potential NDA resubmission for ZYNQUISTA mid-2026, and Novo Nordisk initiated Phase 1 for LX9851.
Lexicon Pharmaceuticals (NASDAQ: LXRX) entered a loan facility with Hercules Capital providing up to $100 million in borrowing capacity, with an initial $55 million funded at closing to repay an existing facility. The facility includes two optional tranches of $20 million and $25 million, a floating rate (prime +3.1%, floor 9.85%), an 18-month interest-only period (two six-month extension options), and maturity by May 4, 2030. Obligations are secured by a first lien on assets and include customary covenants and a minimum cash covenant effective June 1, 2027.
Lexicon Pharmaceuticals (Nasdaq: LXRX) will report first quarter 2026 financial results on May 7, 2026 before the market opens. Management will host a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) to discuss results and provide a business update.
Access the live webcast via the company Events page and use the dial-in to ask questions; an archived webcast will be posted after the call.
Lexicon (NASDAQ:LXRX) will present Phase 2b and preclinical data at the American Academy of Neurology Annual Meeting, April 18-22, 2026 in Chicago.
Key points: PROGRESS data support selection of pilavapadin 10 mg for Phase 3 in diabetic peripheral neuropathic pain after a nominally significant reduction in Average Pain at Week 8 and concordant improvements in Worst and Least Daily Pain. The 10 mg dose was generally well-tolerated over 8 weeks. Lexicon will also present preclinical spasticity data on April 20.
Lexicon (Nasdaq: LXRX) announced three sotagliflozin presentations at the American College of Cardiology Annual Meeting, March 28-30, 2026 in New Orleans. Data include a prespecified SCORED analysis showing reductions in heart failure and MACE across BMI strata and SOTA-P-CARDIA results showing improved quality of life and reduced epicardial adipose tissue in non‑diabetic HFpEF.
Presentations occur March 28: two SOTA-P-CARDIA posters on symptoms/function and fat reduction, and a SCORED poster on BMI-stratified efficacy.
Lexicon Pharmaceuticals (Nasdaq: LXRX) and Novo Nordisk announced initiation of a Phase 1 study of LX9851, an oral non-incretin candidate for obesity.
Lexicon earned a second $10 million milestone in 2026, may earn a third this year, and is eligible for up to $1 billion in total payments plus tiered royalties. The 96-subject trial is expected to complete in Q1 2027.
Lexicon (NASDAQ: LXRX) will present post hoc clinical data on sotagliflozin at ATTD on March 12, 2026, assessing kidney function's effect on one-year efficacy and safety in type 1 diabetes.
Using pooled 52-week placebo-controlled trials, sotagliflozin (200 mg, 400 mg) improved HbA1c, body weight, systolic blood pressure and reduced total insulin use and clinically important hypoglycemia in patients with normal and mildly reduced kidney function; effects were less pronounced in CKD Class 3A. Lexicon plans an NDA resubmission for ZYNQUISTA (sotagliflozin) in 2026.
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q4 and full-year 2025 results and clinical updates on March 5, 2026. Total revenues were $5.5M Q4 and $49.8M FY2025, net loss was $15.5M Q4 and $50.3M FY2025, and cash was $125.2M at year-end.
Key pipeline milestones: SONATA-HCM >50% enrolled, expected topline Q1 2027; NDA resubmission for T1D planned in 2026 if STENO1 data meet FDA requirements; pilavapadin cleared for Phase 3 by FDA End-of-Phase 2. In Feb 2026 Lexicon received >$100M in new cash including ~$96.7M equity proceeds and a $10M Novo Nordisk milestone.